Your browser doesn't support javascript.
loading
Genetic and Clinical Characteristics of Central Serous Chorioretinopathy With Steroid Use.
Yoneyama, Seigo; Fukui, Ayumi; Sakurada, Yoichi; Terao, Nobuhiro; Kusada, Natsuki; Kikushima, Wataru; Kotoda, Yumi; Mabuchi, Fumihiko; Sotozono, Chie; Kashiwagi, Kenji.
Affiliation
  • Yoneyama S; Department of Ophthalmology, University of Yamanashi, Yamanashi, JPN.
  • Fukui A; Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, JPN.
  • Sakurada Y; Department of Ophthalmology, University of Yamanashi, Yamanashi, JPN.
  • Terao N; Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, JPN.
  • Kusada N; Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, JPN.
  • Kikushima W; Department of Ophthalmology, University of Yamanashi, Yamanashi, JPN.
  • Kotoda Y; Department of Ophthalmology, University of Yamanashi, Yamanashi, JPN.
  • Mabuchi F; Department of Ophthalmology, University of Yamanashi, Yamanashi, JPN.
  • Sotozono C; Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, JPN.
  • Kashiwagi K; Department of Ophthalmology, University of Yamanashi, Yamanashi, JPN.
Cureus ; 16(4): e58631, 2024 Apr.
Article de En | MEDLINE | ID: mdl-38770465
ABSTRACT

PURPOSE:

To compare the genetic and clinical characteristics of central serous chorioretinopathy (CSC) in patients with and without steroid use.

METHODS:

A total of 407 consecutive patients with CSC were included. Demographic data and clinical factors, including subfoveal choroidal thickness, bilateral involvement, descending tracts, pachydrusen, fibrin, and dome-shaped pigment epithelial detachment, were obtained. Variants of complement factor H (CFH) I62V (rs800292) and rs1329428 were genotyped in all cases using TaqMan technology.

RESULTS:

Of the total patients, 48 (11.8%) were steroid users. The majority of males were non-steroid users (82.5%) than steroid users (58.3%) (p = 9.8 × 10-5). Demographic data and the prevalence of clinical factors were comparable between the two groups (all p-values > 0.10). Risk allele frequencies of CFH rs800292 and rs1329428 were also comparable between the two groups (p = 0.76, rs800292 steroid users = 52.1% vs. non-steroid users = 50.4%; p = 0.62, rs1329428 steroid users = 47.9% vs. non-steroid users = 45.3%).

CONCLUSIONS:

Except for the male/female ratio, there were no significant differences in the clinical presentation or genetic characteristics, including variants of the CFH gene, between the two groups.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Cureus Année: 2024 Type de document: Article Pays de publication: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Cureus Année: 2024 Type de document: Article Pays de publication: États-Unis d'Amérique